Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2023-12-01 Sale | 2023-12-05 7:40 pm | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer | 10,000 | $60 | $600,000 | 107,690 (Direct) | View |
2023-09-06 Sale | 2023-09-07 4:08 pm | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer | 1,756 | $43.01 | $75,526 | 68,299 (Direct) | View |
2022-05-27 Sale | 2022-05-31 4:30 pm | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 10,000 | $43 | $430,000 | 42,233 (Direct) | View |
2022-04-05 Sale | 2022-04-06 4:10 pm | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 609 | $60.09 | $36,593 | 101,624 (Direct) | View |
2022-04-04 Sale | 2022-04-05 4:08 pm | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 3,504 | $56.96 | $199,589 | 102,233 (Direct) | View |
2022-04-01 Sale | 2022-04-04 5:03 pm | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 11,496 | $55.05 | $632,855 | 105,737 (Direct) | View |
2022-02-11 Sale | 2022-02-14 6:20 pm | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 1,666 | $46.8 | $77,969 | 51,513 (Direct) | View |
2022-02-10 Sale | 2022-02-14 4:15 pm | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 10,000 | $50 | $500,000 | 118,179 (Direct) | View |
2022-02-08 Sale | 2022-02-10 08:32 am | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 10,000 | $45 | $450,000 | 128,857 (Direct) | View |
2022-01-31 Sale | 2022-02-01 5:58 pm | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 1,233 | $38.47 | $47,434 | 53,857 (Direct) | View |
2021-06-10 Sale | 2021-06-11 4:07 pm | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 3,417 | $60 | $205,020 | 26,651 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2023-12-01 Exercise | 2023-12-05 7:40 pm | N/A 2029-02-07 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer | 10,000 | $0 | 107,690 (Direct) | View |
2023-12-01 Exercise | 2023-12-05 7:40 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer | 10,000 | $13.85 | 107,690 (Direct) | View |
2023-02-21 Tax Withholding | 2023-02-22 06:49 am | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer | 715 | $58.5 | 83,666 (Direct) | View |
2023-02-21 Option Award | 2023-02-22 06:49 am | N/A 2032-01-20 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer | 23,909 | $0 | 83,666 (Direct) | View |
2023-02-10 Tax Withholding | 2023-02-14 4:44 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer | 678 | $51.21 | 60,472 (Direct) | View |
2023-01-27 Tax Withholding | 2023-01-30 5:03 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer | 542 | $52.77 | 61,150 (Direct) | View |
2023-01-20 Tax Withholding | 2023-01-24 5:22 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer | 2,015 | $52.05 | 61,692 (Direct) | View |
2023-01-12 Option Award | 2023-01-17 7:42 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer | 22,580 | $0 | 99,179 (Direct) | View |
2023-01-12 Option Award | 2023-01-17 7:42 pm | N/A 2033-01-11 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS Chief Research Officer | 35,472 | $52.66 | 99,179 (Direct) | View |
2022-04-21 Other | 2022-05-31 4:30 pm | N/A 2031-01-27 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 13,125 | $0 | 42,233 (Direct) | View |
2022-04-05 Exercise | 2022-04-06 4:10 pm | N/A 2029-02-07 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 609 | $0 | 101,624 (Direct) | View |
2022-04-05 Exercise | 2022-04-06 4:10 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 609 | $13.85 | 101,624 (Direct) | View |
2022-04-04 Exercise | 2022-04-05 4:08 pm | N/A 2029-02-07 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 3,504 | $0 | 102,233 (Direct) | View |
2022-04-04 Exercise | 2022-04-05 4:08 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 3,504 | $13.85 | 102,233 (Direct) | View |
2022-04-01 Exercise | 2022-04-04 5:03 pm | N/A 2029-02-07 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 11,496 | $0 | 105,737 (Direct) | View |
2022-04-01 Exercise | 2022-04-04 5:03 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 11,496 | $13.85 | 105,737 (Direct) | View |
2022-02-14 Exercise | 2022-02-15 4:58 pm | N/A 2028-04-12 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 720 | $0 | 186,010 (Direct) | View |
2022-02-14 Exercise | 2022-02-15 4:58 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 720 | $26.73 | 186,010 (Direct) | View |
2022-02-10 Exercise | 2022-02-14 4:15 pm | N/A 2029-02-07 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 10,000 | $0 | 118,179 (Direct) | View |
2022-02-10 Tax Withholding | 2022-02-14 4:15 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 678 | $47.12 | 118,179 (Direct) | View |
2022-02-10 Exercise | 2022-02-14 4:15 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 10,000 | $13.85 | 118,179 (Direct) | View |
2022-02-08 Exercise | 2022-02-10 08:32 am | N/A 2029-02-07 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 10,000 | $0 | 128,857 (Direct) | View |
2022-02-08 Exercise | 2022-02-10 08:32 am | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 10,000 | $13.85 | 128,857 (Direct) | View |
2022-01-28 Tax Withholding | 2022-02-01 5:58 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 642 | $38.59 | 53,857 (Direct) | View |
2022-01-21 Option Award | 2022-01-25 4:58 pm | N/A 2032-01-20 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 63,002 | $0 | 92,683 (Direct) | View |
2022-01-21 Exercise | 2022-01-24 5:26 pm | N/A 2028-04-12 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 3,021 | $0 | 164,178 (Direct) | View |
2022-01-21 Exercise | 2022-01-24 5:26 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 3,021 | $26.73 | 164,178 (Direct) | View |
2021-02-10 Tax Withholding | 2021-02-11 4:18 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 680 | $47.72 | 29,290 (Direct) | View |
2021-01-28 Option Award | 2021-02-01 4:39 pm | N/A 2031-01-27 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 65,625 | $0 | 86,220 (Direct) | View |
2020-12-08 Exercise | 2020-12-09 5:34 pm | N/A 2028-04-12 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 7,482 | $0 | 158,113 (Direct) | View |
2020-12-08 Exercise | 2020-12-09 5:34 pm | N/A N/A | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS CHIEF INNOVATION OFFICER | 7,482 | $26.73 | 158,113 (Direct) | View |
2020-02-10 Option Award | 2020-02-12 5:13 pm | N/A 2030-02-09 | Apellis Pharmaceuticals Inc. | APLS | SCHEIBLER LUKAS See Remarks | 65,625 | $0 | 68,560 (Direct) | View |